VBLT Vascular Biogenics Ltd.

+0  (0%)
Previous Close 5.20
Open 5.15
Price To book 3.30
Market Cap 139.89M
Shares 26,902,000
Volume 147,028
Short Ratio 2.09
Av. Daily Volume 85,894

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial met primary endpoint. Overall survival data released November 29, 2016 with full data released February 21, 2017.
Thyroid cancer
Phase 3 trial to be initiated 2H 2017.
Recurrent platinum resistant ovarian cancer
Phase 3 completion of enrollment announced January 6, 2017. Interim analysis due mid-2017. Full data due early 2018.
Recurrent glioblastoma (rGBM) cancer
Phase 2 failed to meet endpoints - Feb 2015 data
Ulcerative colitis
Phase 2 failed to meet endpoints - Feb 2015 data

Latest News

  1. VBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM
  2. VBL Therapeutics Presents Data on MOSPD2, a Novel Immuno-Oncology Target
  3. VBL Therapeutics Presents New Data Supporting Use of Lecinoxoids in NASH
  4. VBL Therapeutics to Present at the H.C. Wainwright NASH Investor Conference
  5. Edited Transcript of VBLT earnings conference call or presentation 27-Mar-17 12:30pm GMT
  6. VBL Therapeutics Announces Fourth Quarter and Year End 2016 Financial Results
  7. VBL Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference
  8. VBL Therapeutics to Present at the 29th Annual ROTH Conference
  9. VBL Therapeutics to Report Full-Year 2016 Financial Results on March 27
  10. VBL Therapeutics Thyroid Cancer Drug Clears Phase 2
  11. VBL Therapeutics Reports Full Data for VB-111 Monotherapy in Phase 2 Trial for Recurrent Thyroid Cancer
  12. VBL Therapeutics to Present at the 2017 BIO CEO & Investor Conference
  13. VBL Therapeutics Announces Publication of Research on a Potential Novel Immuno-Oncology Target
  14. How Xenon Pharmaceuticals Inc (XENE) Stacks Up Against Its Peers
  15. Vascular Biogenics Ltd. :VBLT-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
  16. Earnings Estimates Moving Higher for Vascular Biogenics (VBLT): Time to Buy?